Difference between revisions of "Tislelizumab (Baizean)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| Line 17: | Line 17: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| − | [[Category:Nasopharyngeal | + | [[Category:Nasopharyngeal carcinoma medications]] |
[[Category:Non-small cell lung cancer, nonsquamous medications]] | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] | ||
Revision as of 17:08, 16 September 2022
Note: Tislelizumab is approved in China for multiple indications, but does not appear to have a brand name at this time.
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, nonsquamous
- Non-small cell lung cancer, squamous
Also known as
- Code name: BGB-A317